Skip to main content

Addex Therapeutics Ltd. (NASDAQ: ADXN) Records 52-Week High Tuesday Morning

Shares of Addex Therapeutics Ltd. (NASDAQ: ADXN) traded at a new 52-week high today and are currently trading at $26.19. So far today, approximately 92,023 shares have been exchanged, as compared to an average 30-day volume of 25,537 shares.

Addex Therapeutics Ltd., a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia and ADX71149 for epilepsy and undisclosed CNS disorders.

Addex Therapeutics Ltd. share prices have moved between a 52-week high of $26.47 and a 52-week low of $5. The stock has moved 41.84% over the past week.

To learn more about Addex Therapeutics Ltd., visit the company’s website at

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

Los Angeles, California
310.299.1717 Office

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.